MBNL1 regulates resistance of HeLa cells to cisplatin via Nrf2

Ting Wang; Qiong Liu; Lian Duan

doi:10.1016/j.bbrc.2019.11.162

MBNL1 regulates resistance of HeLa cells to cisplatin via Nrf2

Biochem Biophys Res Commun. 2020 Feb 12;522(3):763-769. doi: 10.1016/j.bbrc.2019.11.162. Epub 2019 Nov 29.

Authors

Ting Wang¹, Qiong Liu², Lian Duan³

Affiliations

¹ Obstetrics and Gynecology Department, Yuncheng County People's Hospital, Shandong Province, China.
² Clinical Laboratory, Hubei University Hospital, Hubei Province, China.
³ Surgery, Hubei University Hospital, Hubei Province, China. Electronic address: superdaddy@163.com.

PMID: 31791583
DOI: 10.1016/j.bbrc.2019.11.162

Abstract

Chemotherapy is an important method in the treatment of cervical cancer, but some patients will face drug resistance, which often indicates a poor prognosis. Moreover, there is no complete solution at present. Therefore, it is urgent to study the drug resistance mechanism of cervical cancer. Based on sequencing data mining, we predicted that MBNL1 might be involved in the occurrence and poor prognosis of cervical cancer, and verifed that MBNL1 could regulate the resistance of HeLa cells to cisplatin via Nrf2. In addition, we demonstrated that MBNL1 up regulated the degradation of Nrf2 protein by increasing the mRNA stability of Cul3. These results can provide theoretical basis for clinical development of new diagnosis and treatment targets for cisplatin resistance.

Keywords: Cisplatin resistance; Cul3; HeLa; MBNL1; Nrf2.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / pharmacology*
Cisplatin / pharmacology*
Drug Resistance, Neoplasm
Female
HeLa Cells
Humans
NF-E2-Related Factor 2 / metabolism*
RNA-Binding Proteins / metabolism*
Uterine Cervical Neoplasms / drug therapy*
Uterine Cervical Neoplasms / metabolism

Substances

Antineoplastic Agents
MBNL1 protein, human
NF-E2-Related Factor 2
NFE2L2 protein, human
RNA-Binding Proteins
Cisplatin